Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
05:35:49 EDT Sat 20 Apr 2024
Enter Symbol
or Name
USA
CA



Q:RVNC - REVANCE THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
RVNC - Q1.03.74·3.881.43.78-0.01-0.31,647.45,7567,9663.80  3.87  3.7137.98  3.62516:05:45Apr 1215 min RT 2¢

Recent Trades - Last 10 of 7966
Time ETExPriceChangeVolume
16:05:45Q3.87970.08972
16:03:44Q3.78-0.01700
16:03:40Q3.78-0.01498
16:03:32Q3.78-0.01439
16:03:29Q3.78-0.01156
16:03:26Q3.78-0.011,416
16:03:19Q3.78-0.014,815
16:02:58Q3.78-0.01420
16:02:50Q3.78-0.011,575
16:02:20Q3.78-0.01179

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-12 08:00U:RVNCNews ReleaseRevance to Present New DAXXIFY(TM) Data at the American Academy of Neurology 2024 Annual Meeting
2024-03-27 16:05U:RVNCNews ReleaseRevance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-04 09:25U:RVNCNews ReleaseRevance Announces Pricing of $100.0 Million Public Offering of Common Stock
2024-03-04 06:37U:RVNCNews ReleaseRevance Announces Proposed Public Offering of Common Stock
2024-02-28 16:05U:RVNCNews ReleaseRevance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update
2024-02-21 08:01U:RVNCNews ReleaseRevance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024
2024-02-21 08:00U:RVNCNews ReleaseRevance to Participate in Upcoming Investor Conferences
2024-02-02 08:00U:RVNCNews ReleaseRevance Receives Permanent J-Code for DAXXIFY ‚ ® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology ‚ ®
2024-02-01 08:00U:RVNCNews ReleaseRevance to Participate in the Guggenheim 6th Annual Biotechnology Conference
2024-01-08 08:00U:RVNCNews ReleaseRevance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook
2023-11-08 16:06U:RVNCNews ReleaseRevance Reports Third Quarter 2023 Financial Results, Provides Corporate Update
2023-11-08 16:05U:RVNCNews ReleaseRevance Appoints Erica Jordan as Chief Commercial Officer, Aesthetics
2023-11-06 08:00U:RVNCNews ReleaseRevance to Participate in Upcoming Investor Conferences
2023-11-01 08:00U:RVNCNews ReleaseRevance to Release Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
2023-10-26 08:00U:RVNCNews ReleaseDAXXIFY ‚ ® Becomes First Facial Injectable to be Named to TIME ¢ € ™s Best Inventions
2023-09-19 09:00U:RVNCNews ReleaseRevance Provides Corporate Update at Investor Day
2023-08-22 08:00U:RVNCNews ReleaseRevance to Host Investor Day on September 19, 2023
2023-08-14 08:00U:RVNCNews ReleaseU.S. FDA Approves First Therapeutic Indication for Revance ¢ € ™s DAXXIFY ‚ ® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
2023-08-08 16:05U:RVNCNews ReleaseRevance Reports Second Quarter 2023 Financial Results, Provides Corporate Update
2023-08-01 08:00U:RVNCNews ReleaseRevance to Release Second Quarter 2023 Financial Results on Tuesday, August 8, 2023